Get the Stockscreener App
10.46
9.52%
-1.10
After Hours:
10.56
0.10
+0.96%
Sionna Therapeutics Inc stock is traded at $10.46, with a volume of 143.84K.
It is down -9.52% in the last 24 hours and down -24.04% over the past month.
See More
Previous Close:
$11.56
Open:
$10.9
24h Volume:
143.84K
Relative Volume:
1.20
Market Cap:
$532.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.55%
1M Performance:
-24.04%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.27
$10.90
1-Week Range:
$10.27
$13.35
52-Week Range:
$10.27
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
10.46 | 532.27M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
Sionna Therapeutics Inc Stock (SION) Latest News
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
SIONSionna Therapeutics Latest Stock News & Market Updates - StockTitan
Pre-market Movers: REVB, QSI, EYEN, NAOV ... - RTTNews
Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Sionna Therapeutics, Inc.’s Quiet Period To Expire on March 19th (NASDAQ:SION) - Defense World
February financings slowing, but year outpaces 2022-2023 - BioWorld Online
Guggenheim Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports - Investorideas.com newswire
Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
Stifel Nicolaus Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - Defense World
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated at TD Cowen - Defense World
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics (NASDAQ:SION) Now Covered by Stifel Nicolaus - MarketBeat
TD Cowen Initiates Sionna Therapeutics at Buy -March 04, 2025 at 07:57 am EST - Marketscreener.com
Guggenheim Initiates Sionna Therapeutics at Buy With $45 Price Target -March 04, 2025 at 07:58 am EST - Marketscreener.com
Stifel Initiates Sionna Therapeutics at Buy With $32 Price Target -March 04, 2025 at 07:57 am EST - Marketscreener.com
TD Cowen initiates Sionna Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation - TipRanks
Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market - TipRanks
Sionna Therapeutics: Innovative NBD1 Stabilizers and Strategic Synergies Drive Buy Rating - TipRanks
Guggenheim sets Sionna stock Buy rating, $45 target By Investing.com - Investing.com Canada
Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis - The Pharma Letter
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market - Yahoo Finance
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference - The Manila Times
Can This Clinical-Stage CF Treatment Developer Disrupt a $10B+ Market? Key Presentation Coming - Stock Titan
Sionna Therapeutics (SION) Surges in Nasdaq Debut Before Paring Gains - HPBL
Atlas Venture Fund Xi L.P Reports 6.5% Stake In Sionna Therapeutics As Of Feb 10 - Marketscreener.com
The Surprising Stock Insiders Can’t Stop Buying: What’s the Hype? - MotoPaddock
Sionna Therapeutics: The Biotech Stock Insiders Are Snapping Up! - Smartphone Magazine
Sionna Therapeutics: The Under-the-Radar Insider Favorite You’ve Been Missing - Anexartiti
Biopharma Gamble: Why Insiders Are Betting Big on Sionna Therapeutics - DSA
Why Insiders Are Betting Big on Sionna Therapeutics This Year - Bit Perfect Solutions
The Biopharma Gamble: Why Insiders Are Banking on Sionna Therapeutics - Elblog.pl
Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? - Insider Monkey
10 Stocks Insiders Are Buying This Year - Insider Monkey
A Buffett Buy, a Biotech IPO, and Other Big Insider Buying - 24/7 Wall St.
Sionna therapeutics sees $20.25 million stock purchase by TPG - MSN
Sionna Therapeutics’ $219.2 Million Upsized IPO - Global Legal Chronicle
Major Stock Acquisition Signals Confidence in Sionna Therapeutics - TipRanks
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):